Home » Topics » Regulatory

Regulatory
RSS

FDA approves liquid formulation of Celexa for treatment of depression

Jan. 10, 2000

No Comments

The antiplatelet agent triflusal now shown to inhibit NF-kappaB activation

Jan. 10, 2000

No Comments

Olanzapine and fluoxetine in combination useful for refractory depression

Jan. 10, 2000

No Comments

Miltefosine tested as oral treatment for leishmaniasis

Jan. 4, 2000

No Comments

CFC-free flunisolide to be developed by 3M/Forest partnership

Jan. 3, 2000

No Comments

NDA filed for intranasal scopolamine during fourth quarter

Jan. 3, 2000

No Comments

FDA approves Ligand's Targretin Capsules for treatment of CTCL

Dec. 30, 1999

No Comments

AstraZeneca seeks approval of Atacand HCT in the U.S.

Dec. 30, 1999

No Comments

Reboxetine + pindolol rapidly relieves symptoms of depression and other CNS disorders

Dec. 30, 1999

No Comments

Injectable levocarnitine approved for use in dialysis in U.S.

Dec. 28, 1999

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Regulatory
RSS

FDA approves liquid formulation of Celexa for treatment of depression

The antiplatelet agent triflusal now shown to inhibit NF-kappaB activation

Olanzapine and fluoxetine in combination useful for refractory depression

Miltefosine tested as oral treatment for leishmaniasis

CFC-free flunisolide to be developed by 3M/Forest partnership

NDA filed for intranasal scopolamine during fourth quarter

FDA approves Ligand's Targretin Capsules for treatment of CTCL

AstraZeneca seeks approval of Atacand HCT in the U.S.

Reboxetine + pindolol rapidly relieves symptoms of depression and other CNS disorders

Injectable levocarnitine approved for use in dialysis in U.S.

Today's news in brief

Today's news in brief

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

Australia’s Celosia heads toward clinic with gene therapy for ALS

Sangamo stock plunges as Pfizer leaves hemophilia partnership

Regulatory RSS

Regulatory
RSS